123 studies found for:    "Gall bladder cancer"
Show Display Options
Rank Status Study
1 Recruiting Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed By Surgery
Conditions: Adult Primary Cholangiocellular Carcinoma;   Advanced Adult Primary Liver Cancer;   Cholangiocarcinoma of the Extrahepatic Bile Duct;   Cholangiocarcinoma of the Gallbladder;   Localized Unresectable Adult Primary Liver Cancer;   Metastatic Extrahepatic Bile Duct Cancer;   Recurrent Adult Primary Liver Cancer;   Recurrent Childhood Liver Cancer;   Recurrent Extrahepatic Bile Duct Cancer;   Recurrent Gallbladder Cancer;   Stage C Adult Primary Liver Cancer (BCLC);   Stage D Adult Primary Liver Cancer (BCLC);   Stage II Gallbladder Cancer;   Stage III Childhood Liver Cancer;   Stage IIIA Gallbladder Cancer;   Stage IIIB Gallbladder Cancer;   Stage IV Childhood Liver Cancer;   Stage IVA Gallbladder Cancer;   Stage IVB Gallbladder Cancer;   Unresectable Extrahepatic Bile Duct Cancer
Interventions: Drug: trametinib;   Drug: leucovorin calcium;   Drug: fluorouracil;   Drug: capecitabine;   Other: laboratory biomarker analysis
2 Completed Triapine and Gemcitabine Hydrochloride in Treating Patients With Bile Duct or Gallbladder Cancer That is Metastatic or Cannot Be Removed By Surgery
Conditions: Adenocarcinoma of the Extrahepatic Bile Duct;   Metastatic Extrahepatic Bile Duct Cancer;   Stage II Gallbladder Cancer;   Stage IIIA Gallbladder Cancer;   Stage IIIB Gallbladder Cancer;   Stage IVA Gallbladder Cancer;   Stage IVB Gallbladder Cancer;   Unresectable Extrahepatic Bile Duct Cancer
Interventions: Drug: triapine;   Drug: gemcitabine hydrochloride
3 Completed S0514 Sorafenib in Treating Patients With Unresectable or Metastatic Gallbladder Cancer or Cholangiocarcinoma
Conditions: Adenocarcinoma of the Extrahepatic Bile Duct;   Adenocarcinoma of the Gallbladder;   Adenocarcinoma With Squamous Metaplasia of the Gallbladder;   Cholangiocarcinoma of the Extrahepatic Bile Duct;   Cholangiocarcinoma of the Gallbladder;   Recurrent Extrahepatic Bile Duct Cancer;   Recurrent Gallbladder Cancer;   Squamous Cell Carcinoma of the Gallbladder;   Unresectable Extrahepatic Bile Duct Cancer;   Unresectable Gallbladder Cancer
Interventions: Drug: sorafenib tosylate;   Other: laboratory biomarker analysis
4 Active, not recruiting
Has Results
S0941 Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gallbladder Cancer or Cholangiocarcinoma
Conditions: Adenocarcinoma of the Extrahepatic Bile Duct;   Adenocarcinoma of the Gallbladder;   Adenocarcinoma With Squamous Metaplasia of the Gallbladder;   Anaplastic Carcinoma of the Gallbladder;   Cholangiocarcinoma of the Extrahepatic Bile Duct;   Cholangiocarcinoma of the Gallbladder;   Recurrent Extrahepatic Bile Duct Cancer;   Recurrent Gallbladder Cancer;   Unresectable Extrahepatic Bile Duct Cancer;   Unresectable Gallbladder Cancer
Interventions: Drug: sorafenib tosylate;   Drug: erlotinib hydrochloride
5 Terminated BMS-247550 in Treating Patients With Liver or Gallbladder Cancer
Conditions: Adult Primary Cholangiocellular Carcinoma;   Adult Primary Hepatocellular Carcinoma;   Advanced Adult Primary Liver Cancer;   Cholangiocarcinoma of the Extrahepatic Bile Duct;   Cholangiocarcinoma of the Gallbladder;   Localized Extrahepatic Bile Duct Cancer;   Localized Gallbladder Cancer;   Localized Resectable Adult Primary Liver Cancer;   Localized Unresectable Adult Primary Liver Cancer;   Recurrent Adult Primary Liver Cancer;   Recurrent Extrahepatic Bile Duct Cancer;   Recurrent Gallbladder Cancer;   Unresectable Extrahepatic Bile Duct Cancer;   Unresectable Gallbladder Cancer
Interventions: Drug: ixabepilone;   Other: laboratory biomarker analysis
6 Recruiting ADH-1, Gemcitabine Hydrochloride and Cisplatin in Treating Patients With Metastatic Pancreatic or Biliary Tract Cancer That Cannot Be Removed By Surgery
Conditions: Acinar Cell Adenocarcinoma of the Pancreas;   Adenocarcinoma of the Gallbladder;   Adult Primary Cholangiocellular Carcinoma;   Advanced Adult Primary Liver Cancer;   Cholangiocarcinoma of the Gallbladder;   Duct Cell Adenocarcinoma of the Pancreas;   Localized Unresectable Adult Primary Liver Cancer;   Periampullary Adenocarcinoma;   Recurrent Adult Primary Liver Cancer;   Recurrent Gallbladder Cancer;   Recurrent Pancreatic Cancer;   Stage II Gallbladder Cancer;   Stage III Pancreatic Cancer;   Stage IIIA Gallbladder Cancer;   Stage IIIB Gallbladder Cancer;   Stage IV Pancreatic Cancer;   Stage IVA Gallbladder Cancer;   Stage IVB Gallbladder Cancer
Interventions: Drug: ADH-1;   Drug: cisplatin;   Drug: gemcitabine hydrochloride;   Other: laboratory biomarker analysis
7 Terminated Selumetinib and Akt Inhibitor MK-2206 in Treating Patients With Refractory or Advanced Gallbladder or Bile Duct Cancer That Cannot Be Removed By Surgery
Conditions: Adenocarcinoma of the Gallbladder;   Adenocarcinoma With Squamous Metaplasia of the Gallbladder;   Adult Primary Cholangiocellular Carcinoma;   Advanced Adult Primary Liver Cancer;   Cholangiocarcinoma of the Extrahepatic Bile Duct;   Localized Unresectable Adult Primary Liver Cancer;   Metastatic Extrahepatic Bile Duct Cancer;   Recurrent Adult Primary Liver Cancer;   Recurrent Extrahepatic Bile Duct Cancer;   Stage II Gallbladder Cancer;   Stage IIIA Gallbladder Cancer;   Stage IIIB Gallbladder Cancer;   Stage IVA Gallbladder Cancer;   Stage IVB Gallbladder Cancer;   Unresectable Extrahepatic Bile Duct Cancer
Interventions: Drug: selumetinib;   Drug: Akt inhibitor MK2206;   Other: laboratory biomarker analysis;   Other: pharmacogenomic studies;   Procedure: quality-of-life assessment
8 Completed
Has Results
Trastuzumab in Treating Patients With Locally Advanced or Metastatic Gallbladder Cancer or Bile Duct Cancer That Cannot Be Removed by Surgery
Conditions: Adenocarcinoma of the Extrahepatic Bile Duct;   Adenocarcinoma of the Gallbladder;   Malignant Neoplasm;   Recurrent Extrahepatic Bile Duct Cancer;   Recurrent Gallbladder Cancer;   Unresectable Extrahepatic Bile Duct Cancer;   Unresectable Gallbladder Cancer
Interventions: Biological: trastuzumab;   Other: laboratory biomarker analysis
9 Recruiting Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointestinal Malignancies
Conditions: Acinar Cell Adenocarcinoma of the Pancreas;   Adenocarcinoma of the Gallbladder;   Adenocarcinoma of Unknown Primary;   Adult Primary Cholangiocellular Carcinoma;   Advanced Adult Primary Liver Cancer;   Cholangiocarcinoma of the Extrahepatic Bile Duct;   Cholangiocarcinoma of the Gallbladder;   Diffuse Adenocarcinoma of the Stomach;   Duct Cell Adenocarcinoma of the Pancreas;   Intestinal Adenocarcinoma of the Stomach;   Localized Unresectable Adult Primary Liver Cancer;   Metastatic Carcinoma of Unknown Primary;   Metastatic Extrahepatic Bile Duct Cancer;   Mixed Adenocarcinoma of the Stomach;   Mucinous Adenocarcinoma of the Colon;   Mucinous Adenocarcinoma of the Rectum;   Newly Diagnosed Carcinoma of Unknown Primary;   Signet Ring Adenocarcinoma of the Colon;   Signet Ring Adenocarcinoma of the Rectum;   Stage III Pancreatic Cancer;   Stage IIIA Colon Cancer;   Stage IIIA Gallbladder Cancer;   Stage IIIA Gastric Cancer;   Stage IIIA Rectal Cancer;   Stage IIIB Colon Cancer;   Stage IIIB Gallbladder Cancer;   Stage IIIB Gastric Cancer;   Stage IIIB Rectal Cancer;   Stage IIIC Colon Cancer;   Stage IIIC Gastric Cancer;   Stage IIIC Rectal Cancer;   Stage IV Gastric Cancer;   Stage IV Pancreatic Cancer;   Stage IVA Colon Cancer;   Stage IVA Gallbladder Cancer;   Stage IVA Rectal Cancer;   Stage IVB Colon Cancer;   Stage IVB Gallbladder Cancer;   Stage IVB Rectal Cancer;   Unresectable Extrahepatic Bile Duct Cancer
Interventions: Drug: oxaliplatin;   Drug: irinotecan hydrochloride;   Drug: leucovorin calcium;   Drug: fluorouracil;   Other: laboratory biomarker analysis
10 Active, not recruiting MK2206 in Treating Patients With Advanced Refractory Biliary Cancer That Cannot Be Removed by Surgery
Conditions: Advanced Adult Primary Liver Cancer;   Localized Unresectable Adult Primary Liver Cancer;   Metastatic Extrahepatic Bile Duct Cancer;   Metastatic Gallbladder Cancer;   Recurrent Adult Primary Liver Cancer;   Recurrent Gallbladder Cancer;   Unresectable Extrahepatic Bile Duct Cancer;   Unresectable Gallbladder Cancer
Interventions: Drug: Akt inhibitor MK2206;   Other: diagnostic laboratory biomarker analysis;   Other: pharmacological study
11 Terminated EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer
Conditions: Advanced Adult Primary Liver Cancer;   Carcinoma of the Appendix;   Fallopian Tube Cancer;   Gastrointestinal Stromal Tumor;   Localized Extrahepatic Bile Duct Cancer;   Localized Gallbladder Cancer;   Localized Gastrointestinal Carcinoid Tumor;   Localized Resectable Adult Primary Liver Cancer;   Localized Unresectable Adult Primary Liver Cancer;   Metastatic Gastrointestinal Carcinoid Tumor;   Ovarian Sarcoma;   Ovarian Stromal Cancer;   Primary Peritoneal Cavity Cancer;   Recurrent Adult Primary Liver Cancer;   Recurrent Adult Soft Tissue Sarcoma;   Recurrent Colon Cancer;   Recurrent Extrahepatic Bile Duct Cancer;   Recurrent Gallbladder Cancer;   Recurrent Gastric Cancer;   Recurrent Gastrointestinal Carcinoid Tumor;   Recurrent Non-small Cell Lung Cancer;   Recurrent Ovarian Epithelial Cancer;   Recurrent Ovarian Germ Cell Tumor;   Recurrent Pancreatic Cancer;   Recurrent Rectal Cancer;   Recurrent Small Intestine Cancer;   Recurrent Uterine Sarcoma;   Regional Gastrointestinal Carcinoid Tumor;   Small Intestine Adenocarcinoma;   Small Intestine Leiomyosarcoma;   Small Intestine Lymphoma;   Stage 0 Non-small Cell Lung Cancer;   Stage I Adult Soft Tissue Sarcoma;   Stage I Colon Cancer;   Stage I Gastric Cancer;   Stage I Non-small Cell Lung Cancer;   Stage I Ovarian Epithelial Cancer;   Stage I Ovarian Germ Cell Tumor;   Stage I Pancreatic Cancer;   Stage I Rectal Cancer;   Stage I Uterine Sarcoma;   Stage II Adult Soft Tissue Sarcoma;   Stage II Colon Cancer;   Stage II Gastric Cancer;   Stage II Non-small Cell Lung Cancer;   Stage II Ovarian Epithelial Cancer;   Stage II Ovarian Germ Cell Tumor;   Stage II Pancreatic Cancer;   Stage II Rectal Cancer;   Stage II Uterine Sarcoma;   Stage III Adult Soft Tissue Sarcoma;   Stage III Colon Cancer;   Stage III Gastric Cancer;   Stage III Ovarian Epithelial Cancer;   Stage III Ovarian Germ Cell Tumor;   Stage III Pancreatic Cancer;   Stage III Rectal Cancer;   Stage III Uterine Sarcoma;   Stage IIIA Non-small Cell Lung Cancer;   Stage IIIB Non-small Cell Lung Cancer;   Stage IV Adult Soft Tissue Sarcoma;   Stage IV Colon Cancer;   Stage IV Gastric Cancer;   Stage IV Non-small Cell Lung Cancer;   Stage IV Ovarian Epithelial Cancer;   Stage IV Ovarian Germ Cell Tumor;   Stage IV Pancreatic Cancer;   Stage IV Rectal Cancer;   Stage IV Uterine Sarcoma;   Unresectable Extrahepatic Bile Duct Cancer;   Unresectable Gallbladder Cancer
Interventions: Drug: EF5;   Drug: motexafin lutetium;   Other: pharmacological study
12 Completed Erlotinib in Treating Patients With Unresectable Liver, Bile Duct, or Gallbladder Cancer
Conditions: Adult Primary Cholangiocellular Carcinoma;   Adult Primary Hepatocellular Carcinoma;   Advanced Adult Primary Liver Cancer;   Cholangiocarcinoma of the Extrahepatic Bile Duct;   Cholangiocarcinoma of the Gallbladder;   Localized Unresectable Adult Primary Liver Cancer;   Recurrent Adult Primary Liver Cancer;   Recurrent Extrahepatic Bile Duct Cancer;   Recurrent Gallbladder Cancer;   Unresectable Extrahepatic Bile Duct Cancer;   Unresectable Gallbladder Cancer
Interventions: Drug: erlotinib hydrochloride;   Other: laboratory biomarker analysis
13 Completed Combination Chemotherapy in Treating Patients With Unresectable or Metastatic Biliary Tract or Gallbladder Cancer
Conditions: Extrahepatic Bile Duct Cancer;   Gallbladder Cancer;   Liver Cancer
Interventions: Drug: fluorouracil;   Drug: gemcitabine hydrochloride;   Drug: leucovorin calcium
14 Completed Gemcitabine, Oxaliplatin and Panitumumab in Kras/B-raf Wild-Type Biliary Track and Gallbladder Cancer
Conditions: Biliary Tract Cancer;   Gallbladder Cancer
Interventions: Drug: Panitumumab;   Drug: oxaliplatin;   Drug: gemcitabine
15 Completed Gemcitabine Plus Pemetrexed Disodium in Treating Patients With Unresectable or Metastatic Biliary Tract or Gallbladder Cancer
Conditions: Extrahepatic Bile Duct Cancer;   Gallbladder Cancer;   Liver Cancer
Interventions: Drug: gemcitabine hydrochloride;   Drug: pemetrexed disodium
16 Completed Palliative Biliary Stenting on the Quality of Life of Patients With Unresectable Carcinoma Gallbladder With Hiliar Block.
Condition: Gallbladder Cancer
Intervention: Procedure: Biliary stenting
17 Completed Endoscopic Versus Percutaneous Drainage For Hilar Block in Gall Bladder Cancer
Conditions: Gallbladder Cancer;   Obstructive Jaundice
Intervention: Procedure: Endoscopic biliary stenting, Percutaneous biliary stenting
18 Completed Study of Gemcitabine and Carboplatin in the Treatment of Metastatic or Recurrent Cholangiocarcinoma/Gallbladder Cancer
Conditions: Cholangiocarcinoma;   Gallbladder Cancer
Interventions: Drug: Gemcitabine;   Drug: Carboplatin
19 Recruiting Permission to Collect Blood Over Time for Research
Conditions: Pancreatic Cancer;   Gastrointestinal Neoplasms;   Colon Rectal Cancer Adenocarcinoma;   Esophageal Cancer;   Gall Bladder Cancer;   Gastric (Stomach) Cancer;   Gastrooesophageal Cancer;   Gastrointestinal Stromal Tumor (GIST);   Hepatobiliary Neoplasm;   Liver Carcinoma;   Gallbladder Carcinoma;   Bile Duct Carcinoma;   Carcinoma of the Large Intestine;   Anal Cancer
Intervention: Procedure: Observation
20 Unknown  A Randomized, Open, Prospective Clinical Research of Fluorouracil Implant to Improve Surgical Gallbladder Cancer and Bile Duct Cancer
Conditions: Gallbladder Cancer;   Bile Duct Cancer
Intervention: Drug: Fluorouracil implant

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years